Gastric adenocarcinoma is one of the most common and lethal cancers worldwide and is associated with a high frequency of nodal metastasis. The value of multimodality therapy is well-established, but gastric resection and locoregional lymph node dissection are important mainstays in potentially curative therapy. However, there has been considerable regional variation in surgical approach and debate regarding the ideal extent of gastric resection, gastric reconstruction, and extent of lymphadenectomy. This chapter outlines the current evidence in the surgical management of gastric adenocarcinoma. The advent of minimally invasive approaches to gastric operations is also discussed.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.suronc.2021.101689 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Primary squamous cell carcinoma of the pancreas: A case report.
Int J Surg Case Rep
January 2025
Department of Hepatopancreatobiliary Surgery, First People's Hospital of Jiashan County, Jiaxing, Zhejiang Province, China.
Introduction: Primary squamous cell carcinoma (SCC) is a rare type of pancreatic cancer with an extremely low incidence rate and a prognosis that is poorer than that of pancreatic ductal adenocarcinoma.
Presentation Of Case: We report a case of pure pancreatic SCC in an 80-year-old man. Based on the examination before surgical resection, we did not detect any SCC lesions that might have metastasized to the pancreas.
Rare epithelial gastric cancers: a review of the current treatment knowledge.
Ther Adv Med Oncol
January 2025
Department of Precision Medicine, Università degli Studi della Campania 'Luigi Vanvitelli', Naples, Italy.
Gastric cancer (GC), one of the tumours with the highest mortality worldwide, is not a homogeneous disease, showing different features according to location, macroscopic aspect, histotype and molecular alterations. Adenocarcinoma is the most frequent epithelial GC (95%), the remaining 5% comprising rare epithelial tumours with their peculiarities, behaviour and incidence <6 cases/100,000/year. Due to the low number of cases, many aspects must be elucidated in this context.
View Article and Find Full Text PDFCost-Effectiveness of Serum Pepsinogen as a Gastric Cancer Targeted Screening Strategy in the United States.
Gastro Hep Adv
October 2024
Albert Einstein College of Medicine, New York, New York.
Background And Aims: Current gastric cancer (GC) screening modalities are invasive and expensive. Noninvasive screening for GC precursors with serum pepsinogen (PG) may improve early detection and prevention. Test characteristics of PG based on US prospective data was recently reported and used to study the cost-effectiveness of PG screening vs no screening in the US.
View Article and Find Full Text PDFGastric cancer patient with amplification treated with crizotinib achieves long-term survival: a case report.
AME Case Rep
December 2024
Department of Medical Oncology, Affiliated Cancer Hospital of Zhengzhou University (Henan Cancer Hospital), Zhengzhou, China.
Background: Gastric cancer (GC) is one of the leading contributors to global malignancies incidence and mortality worldwide. Advanced GC had a relatively poor prognosis. The emerging of targeted therapy improved the survival and prognosis of GC patients.
View Article and Find Full Text PDFComment on "Complications Following Open Versus Minimally Invasive Resection of Gastric Adenocarcinoma".
J Surg Oncol
January 2025
Department of Gynecology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, Liaoning, China.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!